PharmaCyte Biotech Inc (PMCB)

[Triple9]

To me this is just another indication that $PMCB will be partnering with Janssen. Dr. Sher has a very impressive resume and her experience overseeing 50-70 simultaneous clinical trials is a key piece of information here.

Janssen has a huge product line in Oncology: http://www.janssen.com/products/Oncology

Someone like Dr. Sher would be perfect for managing simultaneous trials of CiaB and the various Janssen medicines for solid tumors.

I know we are all waiting for the IND to be filed. But news like our new CMO Dr. Sher and our new Board member Dr. Abecassis are very strategic and telegraph important information to savvy investors.

Why a new Board member? Maybe because something like a partnership agreement with Janssen required the vote of a full Board of six members. Why a new CMO with an impressive background of being the Principal or Co-Principal Investigator for more than 50 clinical trials? Maybe because CiaB could be used with dozens of different medicines to treat solid tumors. Think about it. Did Dr Sher really leave her post at USC Keck's School of Medicine to join $PMCB to do ONE clinical trial?

LAGUNA HILLS, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the appointment of Linda S. Sher, M.D. as the company’s Chief Medical Officer.

Dr. Sher is a Professor of Clinical Surgery and Director of Clinical Research in the Division of Hepatobiliary and Pancreatic Surgery and Abdominal Organ Transplantation at the University of Southern California’s (USC) Keck School of Medicine. Dr. Sher is also the Chief of the Division of Clinical Research for the Department of Surgery where she oversees the implementation and conduct of clinical trials for the entire department, averaging between 50 and 70 studies at all times. She is also the Vice Chair of the USC Institutional Review Board.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are extremely fortunate to have someone with Dr. Sher’s credentials and experience in such a critically important position as our Chief Medical Officer. Dr. Sher will be responsible for the strategy, direction and execution of PharmaCyte’s clinical development plans, an essential position for a biotech company about to embark upon a pivotal trial in pancreatic cancer.

“Not only will Dr. Sher be a key member of the senior management team, she will oversee our entire clinical research program. Dr. Sher has been the Principal or Co-Principal Investigator on more than 50 clinical trials. This experience is invaluable to PharmaCyte. Dr. Sher is expected to contribute considerably to our success as a biotech company and, most importantly, to a successful pivotal trial in pancreatic cancer.”

http://www.otcmarkets.com/stock/PMCB/news/PharmaCyte-Biotech-Appoints-Dr--Linda-S--Sher-as-Chief-Medical-Officer?id=165496